Summary:
In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater liver fat reduction (CAP score), liver enzyme improvements (ALT, AST, GGT), and enhanced glycemic/lipid control compared to monotherapy with either semaglutide alone or empagliflozin alone, with no unexpected adverse signals supporting the combination approach.
| PICO | Description |
|---|---|
| Population | Overweight/obese adults with type 2 diabetes and NAFLD. |
| Intervention | Combination semaglutide (GLP-1 RA) plus empagliflozin (SGLT2i) for 52 weeks. |
| Comparison | Monotherapy with either semaglutide alone or empagliflozin alone for 52 weeks. |
| Outcome | Greater liver fat reduction (CAP), improved liver enzymes, enhanced HbA1c and lipids. |
Clinical Context
NAFLD affects ~70% of T2D patients. GLP-1 RAs and SGLT2i have complementary hepatic mechanisms.
Clinical Pearls
1. Complementary Mechanisms Produce Additive Benefits: Weight loss + metabolic fuel shifting provide greater hepatic fat mobilization.
2. CAP Score as Non-Invasive Assessment: FibroScan-based monitoring enables tracking without liver biopsy.
3. Liver Enzyme Improvement: Improved ALT, AST, GGT suggest reduced hepatocellular injury.
4. Glycemic and Lipid Co-Benefits: Addresses multiple cardiometabolic risk factors simultaneously.
Practical Application
Consider combination GLP-1 RA + SGLT2i for T2D + NAFLD patients. Either agent can be initiated first based on patient factors. Monitor liver enzymes and consider FibroScan.
Study Limitations
CAP measures fat but not fibrosis/inflammation. Liver biopsy remains gold standard. Limited to T2D patients.
Bottom Line
Combination semaglutide + empagliflozin produces greater liver fat reduction than monotherapy in T2D + NAFLD.
Source: Lin YH, et al. “Semaglutide combined with empagliflozin vs. monotherapy for NAFLD in T2D.” PLoS One, 2024. Read article